- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 in chronic kidney disease
Authors
Keywords
Protein convertase subtilisin/kexin 9, PCSK9, Chronic kidney disease, Nephrotic syndrome, Peritoneal dialysis, Hemodialysis, Renal transplantation, End-stage renal disease
Journal
INTERNATIONAL UROLOGY AND NEPHROLOGY
Volume 49, Issue 6, Pages 1015-1024
Publisher
Springer Nature
Online
2017-01-13
DOI
10.1007/s11255-017-1505-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated HypercholesterolemiaClinical Perspective
- (2016) Mary E. Haas et al. CIRCULATION
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- PCSK9 in diabetic kidney disease
- (2016) Usama Elewa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- PCSK9 inhibitors
- (2016) Andrea Denegri et al. Journal of Cardiovascular Medicine
- Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis
- (2016) Vera Krane et al. KIDNEY INTERNATIONAL
- Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences
- (2016) Nosratola D. Vaziri KIDNEY INTERNATIONAL
- Knowing what we do not know: statin therapy in advanced chronic kidney disease
- (2016) Muh Geot Wong et al. Lancet Diabetes & Endocrinology
- PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR
- (2016) Kyrill S. Rogacev et al. PLoS One
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
- (2015) Hagai Tavori et al. ATHEROSCLEROSIS
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
- (2015) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
- (2015) Paul M. Ridker et al. EUROPEAN HEART JOURNAL
- PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
- (2015) Yuichi J. Shimada et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
- (2015) Robert P. Giugliano et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HDL abnormalities in nephrotic syndrome and chronic kidney disease
- (2015) Nosratola D. Vaziri Nature Reviews Nephrology
- Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study
- (2015) Jennie Lin et al. BMC Nephrology
- Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
- (2015) Jennifer G. Robinson et al. CLINICAL CARDIOLOGY
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy
- (2014) Marcin Konarzewski et al. AMERICAN JOURNAL OF NEPHROLOGY
- PCSK9: From discovery to therapeutic applications
- (2014) Michel Farnier Archives of Cardiovascular Diseases
- Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
- (2014) H. Abujrad et al. ATHEROSCLEROSIS
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy
- (2014) Jennifer G. Robinson et al. CLINICAL CARDIOLOGY
- Isolation and characterization of the circulating truncated form of PCSK9
- (2014) Bomie Han et al. JOURNAL OF LIPID RESEARCH
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
- (2014) Christian Werner et al. VASCULAR PHARMACOLOGY
- Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
- (2013) Kyubok Jin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Causes and consequences of lipoprotein(a) abnormalities in kidney disease
- (2013) Florian Kronenberg Clinical and Experimental Nephrology
- Lipoprotein(a): resurrected by genetics
- (2013) F. Kronenberg et al. JOURNAL OF INTERNAL MEDICINE
- Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
- (2012) Arjan J. Kwakernaak et al. ATHEROSCLEROSIS
- Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
- (2012) Michael T. Lipari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cardiovascular Biomarkers in Chronic Kidney Disease
- (2011) Sun-Hee Park et al. JOURNAL OF RENAL NUTRITION
- Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
- (2011) Charles A. Herzog et al. KIDNEY INTERNATIONAL
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
- (2010) André J. Tremblay et al. JOURNAL OF LIPID RESEARCH
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
- (2009) Bengt C. Fellström et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment
- (2008) Vasilis Tsimihodimos et al. AMERICAN JOURNAL OF NEPHROLOGY
- Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
- (2008) Robert J. Schmidt et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search